Screening Hepatitis Positive Women for… | Clinical Trial

Key information

Conditions

Hepatitis C Blood-Borne Infections Communicable Diseases Digestive System Diseases Flaviviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases RNA Virus Infections Virus Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Algazeerah

Giza, Egypt

About this study

Hepatitius positive women should be screened for congenital anomalies

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pregnant women with hepatitis C virus received treatment during first trimester

Exclusion criteria

pregnant women with hepatitis C virus who didnot receive treatment during first trimester

Treatment and study plan

Ultrasound

Diagnostic Test

screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies

Primary outcomes

the number of pregnant women who will be diagnosed to have fetuses with congenital anomalies

Time frame: within 6 months

the number of pregnant women who will be diagnosed to have fetuses with congenital anomalies by us

Sponsors and collaborators

Lead sponsor

Aljazeera Hospital

Other

Collaborators

National Research Centre, Egypt

Registry information

Official study title

Screening Hepatitis Positive Women for Congenital Anomalies During Pregnancy and Assessment of Liver Status of Women

Important dates

Study start: 2018
Primary completion: 2020
Study completion: 2020
First posted: Jun 10, 2019
Registry last updated: Nov 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed